Clinical DevelopmentThe upcoming Phase 3 trial for IFx-2.0, focusing on first-line treatment with Keytruda, could lead to potential full approval based on progression-free survival data.
Financial PositionTuHURA Biosciences ended the year with cash, cash equivalents, and marketable securities of approximately $12.7 million, which should be sufficient to fund operations into the fourth quarter of 2025.
Merger And AcquisitionTuHURA gains full rights to Kineta's novel VISTA-targeted mAb, KVA12123 upon completion of the merger with Kineta, Inc.